A tolerability and pharmacokinetic study of a new injectable formulation of disodium clodronate in healthy female volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2004, Pages 145-152

  Poli, Gianluigi ^a   Mariotti, Fabrizia ^a   Corrado, Mario Ermanno ^b   Acerbi, Daniela ^a  

^a CHIESI FARMACEUTICI S P A   (Italy)

^b Cross Research SA   (Switzerland)

Author keywords

CAS 22560 50 5; Disodium clodronate; Intramuscular injection; Lidocaine; Tolerability and pharmacokinetics

Indexed keywords

BENZYL ALCOHOL; CLODRONIC ACID; CLODY; CREATINE KINASE; LIDOCAINE; LOCAL ANESTHETIC AGENT;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ERYTHEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; NORMAL HUMAN; OSTEOLYSIS; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL ANALYSIS; URINARY EXCRETION; VERBAL RATING SCORE; VISUAL ANALOG SCALE; VOLUNTEER;

EID: 3042617301     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190589     Document Type: Article

References (29)

1. Fleisch H., Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs, 42 919-944 (1991).
2. Barnett B.L., Strickland L.C., Structure of disodium dihydrogen 1-hydroxyethylidenediphosphonate tetrahydrate: a bone growth regulator. Acta Crystallogr. B, 35 1212-1214 (1979).
3. Jung A., Bisaz S., Fleisch H., The binding of pyrophosphate and two diphosphonate on hydroxyapatite crystals. Calcif. Tissue Res., 11: 269-280 (1973).
4. Ljunghall S., Rastad J., Akerstrom G., Comparative effects of calcitonin and clodronate in hypercalcaemia. Bone, 8 (1) S79-83 (1987).
5. Patel S., Lyons A.R., Hosking D.J., Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use. Drugs, 46 (4) 594-617 (1993).
6. Rossini M., Braga V., Gatti D., et al., Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone, 24 (2) 125-9 (1999).
7. Adami S., Passeri M., Ortolani S., et al., Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone, 17 (4) 383-90 (1995).
8. Reginster J.Y., Lecart M.P., Deroisy R., et al., Prevention of postmenopausal bone loss by tiludronate. Lancet, 2 (8678-8679) 1469-71 (1989).
9. Storm T., Thamsborg G., Steiniche T., et al., Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med., 322 (18) 1265-71 (1990).
10. Valkema R., Vismans F.J., Papapoulos S.E., et al., Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner., 5 (2) 183-92 (1989).
11. Watts N.B., Harris S.T., Genant H.K., et al., Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med., 323 (2) 73-9 (1990).
12. Adami S., Bolzicco G.P., Rizzo A., et al., The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner., 2 (5) 395-404 (1987).
13. Adami S., Guarrera G., Salvagno G. et al., Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (C12MDP). Metab. Bone Dis. Relat. Res., 5 (6) 265-7 (1984).
14. Adami S., Salvagno G., Guarrera G. et al., Dichloromethylene- diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol., 134 (6) 1152-4 (1985).
15. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs, 42 (6) 919-44 (1991).
16. Clodronate: a new perspective in the treatment of neoplastic bone disease. Proceedings of a meeting. Helsinki. Bone, 8 (Suppl 1):S1-86 (1987).
17. Kanis J.A., McCloskey E.V., Paterson A.H., Use of diphosphonates in hypercalcaemia due to malignancy. Lancet, 335 (8682) 170-1 (1990).
18. Yates A.J., Percival R.C., Gray R.E. et al., Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet, 1 (8444) 1474-7 (1985).
19. Kanis J.A., McCloskey E.V., Sirtori P. et al., Rationale for the use of clodronate in osteoporosis. Osteoporos. Int., 3 (2) S23-8 (1993).
20. Kaastad T.S., Reikeras O., Madsen J.E. et al., Effects of clodronate on cortical and trabecular bone in ovariectomized rats on a low calcium diet. Calcif. Tissue Int., 61 (2) 158-64 (1997).
21. Lepola V.T., Hannuniemi R., Kippo K., et al., Long-term effects of clodronate on growing rat bone. Bone, 18 (2) 191-6 (1996).
22. Minaire P., Berard E., Meunier P.J., et al., Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. J. Clin. Invest. 68 (4) 1086-92 (1981).
23. Lin J.H., Bisphosphonates: a review of their pharmacokinetic properties. Bone, 18 (2) 75-85 (1996).
24. Adami S., Zamberlan N., Adverse effects of bisphosphonates. A comparative review. Drug Saf., 14 (3) 158-70 (1996).
25. Filipponi P., Cristallini S., Rizzello E. et al., Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone, 18 (2) 179-84 (1996).
26. Filipponi P., Pedetti M., Fedeli L. et al., Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J. Bone Miner. Res., 10 (5) 697-703 (1995).
27. Heikkinen J.E., Selander K.S., Laitinen K., et al., Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J. Bone Miner. Res., 12 (1) 103-110 (1997).
28. Gnudi S., Lisi L., Fini M., et al., Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women. Int. J. Tissue React., 23 (1), 33-7 (2001).
29. CTFA technical guidelines III. "Pharmacology and toxicology, safety testing guidelines. Guidelines for evaluating contact sensitisation potential", The Cosmetic, Toiletry and Fragrance Association Inc. Washington D.C., USA., Curry (Ed.), pp. 7-9 G.N. Mc Ewen Jr., Anita S. (1981).